89,076 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Bought by 683 Capital Management LLC

683 Capital Management LLC acquired a new stake in Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 89,076 shares of the company's stock, valued at approximately $744,000. 683 Capital Management LLC owned about 0.17% of Alpha Teknova as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in shares of Alpha Teknova by 622.5% in the 4th quarter. JPMorgan Chase & Co. now owns 4,400 shares of the company's stock worth $37,000 after purchasing an additional 3,791 shares during the period. Mount Lucas Management LP purchased a new stake in Alpha Teknova during the 4th quarter worth about $75,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alpha Teknova in the fourth quarter worth about $94,000. NewEdge Advisors LLC grew its position in shares of Alpha Teknova by 14.3% during the 4th quarter. NewEdge Advisors LLC now owns 15,632 shares of the company's stock valued at $131,000 after purchasing an additional 1,953 shares in the last quarter. Finally, Barclays PLC bought a new position in shares of Alpha Teknova in the fourth quarter worth $132,000. 13.81% of the stock is currently owned by institutional investors.

Alpha Teknova Price Performance

TKNO traded up $0.23 on Wednesday, reaching $6.16. The company had a trading volume of 252,261 shares, compared to its average volume of 368,432. Alpha Teknova, Inc. has a 52-week low of $1.16 and a 52-week high of $10.37. The company has a market cap of $329.20 million, a price-to-earnings ratio of -8.34 and a beta of 0.50. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.94 and a current ratio of 4.73. The business has a 50 day simple moving average of $5.74 and a 200 day simple moving average of $7.11.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.11) earnings per share for the quarter. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The company had revenue of $9.27 million for the quarter, compared to analysts' expectations of $9.10 million. As a group, sell-side analysts anticipate that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on Alpha Teknova in a research report on Monday, February 10th. They set a "buy" rating and a $12.00 target price for the company.

Alpha Teknova Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.